UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022

4D MOLECULAR THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-39782**	**47-3506994**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification Number)**

5858 Horton Street #455
Emeryville, California 94608
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (510) 505-2680

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	**FDMT**	**The Nasdaq Global Select Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 10, 2022, 4D Molecular Therapeutics, Inc. (the "Company") provided a corporate presentation relating to its research and development programs by posting a corporate presentation to the investor section of the Company's website at: https://ir.4dmoleculartherapeutics.com. The Company's corporate presentation is attached hereto as Exhibit 99.1.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC") and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled "Legal Disclaimer" in Exhibit 99.1 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation of 4D Molecular Therapeutics, Inc. dated January 10, 2022.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

4D MOLECULAR THERAPEUTICS, INC.

Date: January 11, 2022

By: /s/ August J. Moretti
August J. Moretti
Chief Financial Officer

Exhibit 99.1

Harnessing the Power of Directed Evolution for Targeted Gene Therapies

Corporate Presentation | January 2022

Legal Disclaimer

This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, and objectives of management, are forward looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation.

This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied.

This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

We are Boldly Innovating to Unlock the Full Potential of Gene Therapy for Millions of Patients

COMPANY	**Co-Founders** Kirn, MD & Schaffer, PhD	**Emeryville**	**~120** Employees **GMP** Facilities
PLATFORM	**Directed Evolution**	**~1 BILLION AAV** synthetic capsid sequences	**Targeted & Evolved Vectors**
PIPELINE	**Vector Modularity**	**Lead Vectors & 3 Therapeutic Areas**	
CLINICAL DEVELOPMENT	**5 Clinical Candidates**		
STRATEGY	**Fully Integrated Biopharmaceutical Company**		

Successes & Limitations of Conventional AAV

OPPORTUNITY FOR TARGETED GENE THERAPY VECTORS & PRODUCTS

SUCCESSES

zolgensma®

LUXTURNA®

avexis

Spark Therapeutics

LIMITATIONS

- Limited Delivery
- Limited Transduction
- Increased Inflammation and Toxicity
- Vulnerability to Neutralizing Antibodies

→ Narrow Focus on Niche Diseases

OPPORTUNITY:
UNLOCK THE FULL POTENTIAL OF GENE THERAPY BY HARNESSING THE POWER OF DIRECTED EVOLUTION

Platform Solution: Therapeutic Vector Evolution

INNOVATION BY DIRECTED EVOLUTION

"…the most powerful biological design process…"

– Frances Arnold,
*2018 Nobel Prize in Chemistry**



*Dr. Arnold and the other investigators awarded the Nobel Prize have no affiliation with 4DMT.

Platform Solution: ~1 Billion Synthetic Capsid Sequences

40 DISTINCT LIBRARIES



Platform Solution: Compete for Target Vector Profile Fitness

THERAPEUTIC VECTOR EVOLUTION



*Capsid library placed under varying selective pressures // Actual number of selection rounds varies by target

Modular Approach to Therapeutic Area Pipeline

PRODUCT DESIGN & ENGINEERING FOR ACCELERATED DEVELOPMENT



Pipeline: 5 Clinical-Stage Product Candidates

THREE THERAPEUTIC AREAS, RARE & LARGE PATIENT POPULATIONS

VECTOR *Delivery*	PRODUCT CANDIDATE	INDICATION	LEAD OPTIMIZATION	IND-ENABLING	PHASE 1 / 2	PHASE 3	PRODUCT RIGHTS
R100 *Intravitreal* 	OPHTHALMOLOGY						
	4D-125	XLRP					4DMT
	4D-110	CHM					4DMT
	4D-150	Wet AMD					4DMT
		DME					4DMT
C102 *IV* 	CARDIOLOGY						
	4D-310	Fabry Disease					4DMT
A101 *Aerosol* 	PULMONOLOGY						
	4D-710	Cystic Fibrosis					4DMT

CARDIOLOGY

Modular Vector: C102

- 4D-310: FABRY DISEASE

4D-310 Product Design & C102 Target Vector Profile

INVENTED FOR LOW DOSE IV DELIVERY TO TARGET ORGANS INCLUDING HEART & HIGH SERUM AGA

PRODUCT DESIGN

- **Vector:** C102
- **Transgene:** *GLA* (encodes AGA enzyme)
- **Promoter:** Ubiquitous



4D-310 Competitive Advantages: Dual MOA Product Design

DESIGNED FOR HIGH STABLE AGA EXPRESSION IN BLOOD, HEART & OTHER TARGET ORGANS

		ERT		Gene Therapy		
MOA	**Product Design**	AGA Enzyme Infusions	PEGylated AGA	Autologous Stem Cells	AAV Liver-directed	**4D-310**
AGA: Systemic PK	Pharmacokinetics					
	No chemotherapy/ bone marrow ablation	+	+	–	+	**+**
AGA: Production in Target Cells	Heart, Kidney, Blood Vessels	–	–	–	–	**+**
AGA: Avoid Anti-AGA Ab	Intracellular production	–	–	–	–	**+**

Abbreviations: Ab, antibodies; AGA, aspartylglucosaminidase; AAV, adeno-associated virus; ERT, enzyme replacement therapy; IV, intravenous; n.a., not applicable.

4D-310 Study Design: Broad Enrollment Criteria

OPEN-LABEL, PHASE 1/2 TRIAL IN ADULTS WITH CLASSIC & LATE-ONSET FABRY DISEASE

STUDY DESIGN



ASSESSMENT SCHEDULE: BIOMARKERS

	Screening/Treatment Period				Observation Period										
Visit	SV1	SV2	D-1	D1	D2	D4	D8	D15	W4*	W6	W8	W12	W26	W38	W52 or ET
Visit Window (days)	Up to -180	-45 to -2	–	–	–	±1	±1	±1	±3	±3	±3	±7	±7	±7	±7
Fabry Blood Panel (AGA, lysoGb3); central lab[b]	◆	◆						◆	◆	◆	◆	◆	◆	◆	◆

◆ Biomarker Assessment (Mayo Clinic)

KEY INCLUSION CRITERIA

- Males ≥ 18 years of age
- Pathogenic *GLA* mutation
- Classic **OR** Late-onset FD with LVH
- ERT-On, ERT-Off **OR** ERT-naïve
- Anti-AGA Ab status positive **OR** negative

KEY EXCLUSION CRITERIA

- High titer anti-4D-310 NAb (>1:1,000)
- High titer anti-AGA NAb titer (>1:25,000)
- eGFR <45 mL/min/1.73m2
- LVEF <45% (Echo)

PRIMARY ENDPOINT

- Incidence & severity of adverse events

KEY SECONDARY ENDPOINTS

- **Serum AGA Activity:** change from baseline
- **Cardiac - Imaging & Functional:** change from baseline

4D-310 Baseline Patient Characteristics:

STUDY ENROLLED CLASSIC FABRY DISEASE PATIENTS WITH ANTI-AGA ANTIBODY POSITIVITY

	Patient 1	Patient 2	Patient 3
Age dosed with 4D-310	51 years	32 years	26 years
Anti-AGA antibody titer	1 : 947	**1 : 99,900**	1 : 13,900
Disease classification	**Classic**	**Classic**	**Classic**
Serum AGA activity (nmol/hr/mL)	0.42	0.00	0.30
ERT experience	Yes	Yes	Yes
ERT status	**ERT-ON**	**ERT-OFF**	**ERT-ON**
Serum lyso-Gb3 (ng/mL)	**6.28**	**101.00**	**8.78**
Mutation	c.1023A>C (p.E341D)	c.708G>T (p.W236C)	c.974G>A (p.G325D)

Reference range:
- Serum AGA activity: 4.44-27.42 nmol/hr/mL
- Serum Lyso-Gb3: ≤ 1.0 ng/mL

4D-310 Mean Serum AGA Activity: >20-Fold Mean Normal

ANTI-AGA ANTIBODY POSITIVE LOW & MID TITERS: PATIENTS 1 & 3 AGA ACTIVITY OVER TIME

Mean Serum AGA Activity:

- Patient 1: 248.1 nmol/hr/mL
- Patient 3: 209.3 nmol/hr/mL



Serum AGA activity: mean normal = 9.9 nmol/hr/ml; normal range: 4.44 – 27.42 nmol/hr/mL

4D-310 Mean Serum AGA Activity: Within Normal Range

AGA ANTIBODY POSITIVE HIGHEST TITER: PATIENT 2 (HIGHEST TITER OF ALL ENROLLED & SCREENED)

Mean Serum AGA Activity:

- Patient 2: 5.7 nmol/hr/mL



Serum lyso-Gb3:



Serum AGA activity: mean normal = 9.9 nmol/hr/ml; normal range: 4.44 – 27.42 nmol/hr/mL;

Summary of Interim Data: 4D-310 Ph 1/2 Clinical Trial

DATA CUT-OFF DATE: 10/12/21

- 4D-310 demonstrated a manageable safety profile & no DLTs
- Clinical activity observed in all patients at all timepoints:
  - Mean **AGA** enzyme activity:
    - Within, or significantly above, the normal range in all three patients
    - Levels correlated with baseline anti-AGA antibody titers
  - Serum **lyso-Gb3** substrate decreased significantly in patient with elevated pre-treatment lysoGb3 (entered study OFF-ERT)
  - Serum lyso-Gb3 substrate remained low following discontinuation of ERT in BOTH patients who entered study ON-ERT

OPHTHALMOLOGY

Modular Vector: R100

- **4D-125:** XLRP
- **4D-150:** wAMD/DME
- **4D-110:** CHOROIDEREMIA

Ophthalmology: R100 Structure & Target Vector Profile

INTRAVITREAL DELIVERY FOR RETINAL DISEASES



Naturally occurring capsid







R100





Abbreviations: ILM, inner limiting membrane; RPE, retinal pigment epithelium.

Ophthalmology: 4D-125 for XLRP

HIGH UNMET MEDICAL NEED

- **Monogenic:** X-linked (*RPGR*)
- **Blinding:** periphery to center
- **NO FDA APPROVED THERAPY**

EPIDEMIOLOGY: US & EU-5

- **~24,000** prevalence



PRODUCT DESIGN

- **Vector:** R100
- **Transgene:** *RPGR*
- **Promoter:** Photoreceptor-specific

DIFFERENTIATION

Intravitreal (IVT)
Transduces Entire Retinal Surface
IVT Routine & Safe
All Stages

STATUS:

Ongoing Phase 1/2 Clinical Trial

Fast Track Designation

EXPECTED MILESTONE:

Ongoing Enrollment at 1E12 vg/eye

4D-125 Study Design

OPEN-LABEL, PHASE 1/2 TRIAL IN ADULTS WITH XLRP

STUDY DESIGN



DSMC review

ASSESSMENT SCHEDULE

Visit	Baseline	Day 14	Mon 2	Mon 4	Mon 6	Mon 9	Mon 12	Mon 15	Mon 18	Mon 21	Mon 24
Visit Window (days)	-7 to Day 1 (Pre-Dose)	±2	±7	±7	±7	±7	±7	±7	±7	±7	±7
Microperimetry (avg. retinal sensitivity & pointwise)	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆
OCT – EZA	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆	◆

Biomarkers assessed by Independent Reading Center

KEY INCLUSION CRITERIA

- Male ≥18 years of age
- Hemizygous RPGR mutation
- Clinical diagnosis of non-syndromic retinitis pigmentosa
- Measurable ellipsoid zone line (EZL) on macular SD-OCT
- Microperimetry:
  - >1 nonzero point (dose-escalation) OR
  - ≥1dB mean retinal sensitivity (dose-expansion)

PRIMARY ENDPOINT

- Incidence & severity of adverse events

KEY SECONDARY ENDPOINTS

- **EZ Area (SD-OCT):** Change from baseline over time vs contralateral non-injected control eye
- **Microperimetry:** Change from baseline in visual field sensitivity & # loci improving >7dB over 12 months vs contralateral non-injected control eye

4D-125 XLRP Biomarker Data: Preliminary Evidence of Activity

BASELINE TO LAST VISIT; N=2 EVALUABLE & WITH AT LEAST 6 MONTHS FOLLOW-UP

		Optical Coherence Tomography (OCT) [Ellipsoid Zone Area – % Change]		Microperimetry [Mean Retinal Sensitivity (dB)]		Microperimetry [# of Loci with ≥ 7dB Improvement]	
Patient	Last Assessment	Treated Eye	Untreated Eye	Treated Eye	Untreated Eye	Treated Eye	Untreated Eye
Cohort 1 (3×10^{11} vg/eye)							
1	Month 12	-1.0%	-2.1%	Not Evaluable	Not Evaluable	Not Evaluable	Not Evaluable
2	Month 12	Not Evaluable	-10.7%	-0.3	Not Evaluable	0	Not Evaluable
3	Month 9	**-12.4%**	-16.2%	**+1.65**	+0.25	**+6**	+1
Cohort 2 (1×10^{12} vg/eye)							
4	Month 6	Not Evaluable	Not Evaluable	Not Evaluable	Not Evaluable	Not Evaluable	Not Evaluable
5	Month 6	**-20.2%**	-28.7%	**+0.90**	+0.10*	**+3**	0*
6	Month 9	Not Evaluable	-7%	Not Evaluable	Not Evaluable	Not Evaluable	Not Evaluable

*Month 4 – Patient 5 unable to fixate in untreated eye at m6

Summary of 4D-125 Interim Phase 1/2 Clinical Data

- 4D-125 well-tolerated with no dose-limiting toxicities, serious adverse events or chronic inflammation
- Evidence of clinical activity observed in the **treated eye vs. the untreated eye** in evaluable patients (2/2 pts) on **three clinical activity endpoints**
- Continuing enrolling patients at high dose (1E12 vg/eye) in expansion cohort, including **less advanced patients**
- **Fast Track Designation** received from FDA

Ophthalmology: 4D-150 for Wet AMD & DME

HIGH UNMET MEDICAL NEED

- Frequent Injections
- Patient / Physician Adherence Issues
- Incomplete Responders

EPIDEMIOLOGY: US

- **Wet AMD: ~200,000/yr** incidence
- **DME: ~1.2M** prevalence
- **$9.7 Billion** 2019 global sales



PRODUCT DESIGN

- **Vector:** R100
- **Transgene 1:** Aflibercept
- **Transgene 2:** VEGF-C RNAi
- **Promoter:** Ubiquitous

DIFFERENTIATION

Intravitreal (IVT)
Transduces Entire Retina Surface
IVT Routine & Safe
4 Distinct Mechanisms-of-action

STATUS:

Ongoing Phase 1/2 Clinical Trial

EXPECTED MILESTONE:

Ongoing Enrollment in Dose Escalation

Ophthalmology: 4D-150 Efficacy in NHP CNV Model

100% SUPPRESSION OF CNV INCLUDING AT LOWEST DOSE OF 1E11 VG/EYE



- 100% suppression of CNV,
- Including at lowest dose of 1E11 vg/eye
- Day 42 ocular assessments prior to laser:
  - 1E11 vg / eye, no uveitis or retinal abnormalities
  - 3E11 & 1E12 vg / eye, mild to moderate uveitis in a minority of NHP; no retinal abnormalities
  - Tapered 28-day steroid regimen

4D-150 Study Design

PHASE 1/2 DOSE-ESCALATION FOLLOWED BY RANDOMIZED DOSE EXPANSION

STUDY DESIGN



KEY INCLUSION CRITERIA

- ≥ 50 years of age
- Diagnosed with CNV secondary to AMD
- Anti-VEGF treatment: minimum 6 injections last 12 mo
- Disease responsive to anti-VEGF treatment

PRIMARY ENDPOINT

- Incidence and severity of adverse events

KEY SECONDARY ENDPOINTS

- **Rescue Aflibercept Injections:** # over time vs pre-treatment

◆ DSMC review

Ophthalmology: 4D-110 for Choroideremia

HIGH UNMET MEDICAL NEED

- **Monogenic:** X-linked (*CHM*)
- **Blinding:** periphery to center
- **NO FDA APPROVED THERAPY**

EPIDEMIOLOGY: US & EU-5

- **~13,000** prevalence



PRODUCT DESIGN

- **Vector:** R100
- **Transgene:** *CHM*
- **Promoter:** Ubiquitous

DIFFERENTIATION

Intravitreal (IVT)
Transduces Entire Retinal Surface
IVT Routine & Safe
All Stages

STATUS:
Ongoing Phase 1/2 Clinical Trial

EXPECTED MILESTONE:
Ongoing Enrollment at 3E11 vg/eye

Key Takeaways for 4D-110 Clinical Data

TOLERABILITY @3E11 VG/EYE ASSOCIATED WITH CLINICAL ACTIVITY

- 3E11 vg/eye dose (Cohort 1):
  - Well-tolerated & no DLT or SAE
  - **Clinical activity vs control eyes (FAF Area)**
- 1E12 vg/eye dose (Cohort 2):
  - AE consistent with REP1 transgene product over-expression (no association with inflammation)
- Dose expansion at 3E11 vg/eye dose (n= 6 total)

PULMONOLOGY

Modular Vector: A101

- 4D-710: CYSTIC FIBROSIS

4D-710 Product Design & A101 Target Vector Profile

AEROSOL DELIVERY FOR LUNG DISEASES

PRODUCT DESIGN

- **Vector:** A101
- **Transgene:** *microCFTR*
- **Promoter:** Ubiquitous



Abbreviations: TVP, Target Vector Profile

Pulmonology: 4D-710 Aerosol Delivery in NHP

WIDESPREAD TRANSDUCTION IN NHP AIRWAYS & ALVEOLI



4D-710	Lung
Genome (qPCR)	46/48 (95.8%)
mRNA (RT-qPCR)	44/48 (91.7%)

4D-710 Study Design

OPEN-LABEL, PHASE 1/2 TRIAL

STUDY DESIGN



KEY INCLUSION CRITERIA

- ≥18 years of age
- Diagnosis of CF lung disease including:
  - Bi-allelic mutations in the *CFTR* gene
  - CFTR modulator therapy:
    - Ineligible **OR**
    - Received modulator therapy but discontinued due to adverse effects or lack of efficacy

PRIMARY ENDPOINT

- Incidence & severity of adverse events

KEY SECONDARY ENDPOINTS

- **Percent Predicted FEV_1 :** change from baseline

MILESTONES & FINANCIALS

Expected Milestones & Cash Runway

4D-150	PH 1/2 DOSE-ESCALATION ON-GOING
4D-125	PH 1/2 DOSE-EXPANSION ON-GOING
4D-110	PH 1/2 DOSE-EXPANSION ON-GOING

4D-310 **1Q22** – UPDATED INTERIM CLINICAL DATA (WORLD SYMPOSIUM 2022)

4D-710 **1H22** – PH 1/2 FIRST PATIENT DOSED

CASH POSITION & RUNWAY GUIDANCE

$227M

Cash, cash equivalents and marketable securities as of the end of Q3 2021

$111M

Net proceeds from October 2021 follow-on public offering

$338M proforma

Cash, cash equivalents & marketable securities expected to fund operations into 2H24

THANK YOU

5858 Horton Street, Suite 455 Emeryville, California 94608
(510) 505-2680 | info@4DMT.com
4DMT.com